Quantitative bone scintigraphy: A methodological evaluation in prostate cancer

Acta Radiologica

Volumn 41, Issue 2, 2000, Pages 183-188

  Rydh, Anders ^a,b   Riklund Ahlstrom K ^a   Larsson, A ^a   Johansson, L ^a   Damber, J E ^a   Tomic R ^a   Hietala, S O ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Prostate cancer, quantitative bone scintigraphy; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; BONE; BONE TUMOR; DISEASE COURSE; HUMAN; IMAGE QUALITY; MALE; METASTASIS; MIDDLE AGED; PROSTATE TUMOR; SCINTILLATION CAMERA; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; DISEASE PROGRESSION; GAMMA CAMERAS; HUMANS; MALE; MIDDLE AGED; PHANTOMS, IMAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0034145181     PISSN: 02841851     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418500127345028     Document Type: Article

References (21)

1. BOLTON D. M.: Detection of relapsed disease - is prostate-specific antigen enough? In: Questions and uncertainties about prostate cancer, p. 255. Edited by W. B. Peeling. Blackwell Science, Oxford 1996.
2. BUSHNELL D. L., KAHN D., HUSTON B. et al.: Utility of SPECT imaging for determination of vertebral metastases in patients with known primary tumors. Skeletal Radiol 24 (1995), 13.
3. CONDON B. R., BUCHANAN R., GARVE N. W. et al.: Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging. Br. J. Radiol. 54 (1981), 18.
4. CORRIE D., TIMMONS J. H., BAUMAN J. M. et al.: Efficacy of follow-up bone scans in carcinoma of the prostate Cancer 61 (1988), 2453.
5. ERDI Y. E., HUMM J. L., IMBRIACO M. et al.: Quantitative bone metastases analysis based on image segmentation. J. Nucl. Med. 38 (1997), 1401.
6. FIGG W. D., AMMERMAN K., PATRONAS N. et al.: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormonerefractory prostate cancer. Cancer Invest. 14 (1996), 513.
7. FLEMING J. S.: A technique for the absolute measurement of activity using a gamma camera and computer Phys. Med. Biol. 24 (1979), 176.
8. FRONT D., ISRAEL O., JERUSHALMI J. et al: Quantitative J bone scintigraphy using SPECT. J. Nucl. Med 30 (1989) 240.
9. JACOBSSON A. F. & FOGELMANN I.: Bone scanning in clinical oncology. Does it have a future? Eur. J. Nucl. Med. 25 (1998), 1219.
10. MODONI S., CALO E., NARDELLA G. et al.: PSA and bone scintigraphy. Int. J. Biol. Markers 12 (1997), 158.
11. OESTERLING J. E.: Using prostate-specific antigen to eliminate unnecessary diagnostic tests. Significant world-wide economic implications. Urology 46 (1995), Suppl. A, p. 26.
12. 99mTc-diphosphonate bone scans and rontgenograms in the detection of prostate, breast and lung carcinoma metastases. AJR 125 (1975), 972.
13. PARKER D. & HART G. C.: Improved sensitivity in bone scintigraphy using quantitative spinal profile analysis. Nucl. Med. Commun. 9 (1988), 631.
14. PARTIN A. W. & OESTERLING J. E.: The clinical usefulness of prostate specific antigen. Update. J. Urol. 152 (1994), 1358.
15. POLLEN J. J. & SHLAER W. J.: Osteoblastic response to successful treatment of metastatic cancer of the prostate. AJR 132 (1979), 927.
16. RYDH A., TOMIC R., TAVELIN B. et al.: The predictive value of prostate-specific antigen (PSA), tumour stage (T) and tumour grade (G) for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer. Scand. J. Urol. Nephrol. 33 (1999), 89.
17. SLACK N. H., KARR J. P., CHU T. M. et al.: An assessment of bone scans for monitoring osseous metastases in patients being treated for prostate carcinoma. Prostate 1 (1980), 259.
18. SOLOWAY M. S., HARDEMAN S. W., MICKEY D. et al.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1988), 195.
19. SUNDKVIST G. M. G., AHLGREN L., LILJA B. et al.: Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchidectomy. Eur. J. Nucl. Med. 14 (1988), 2036.
20. VAN DER WALL H.: The evaluation of malignancy. Metastatic bone disease. In: Nuclear medicine in clinical diagnosis and treatment, p. 949. Edited by I. P. C. Murray & P. J. Ell. Churchill Livingstone, London 1994.
21. VAN RENSBURG A. J., ALBERTS A. S. & LOUW W. K. A.: Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. J. Nucl. Med. 39 (1998), 2110.